On January 17, 2025, WuXi AppTec, a leading global provider of R&D and manufacturing-enabling services in the pharmaceutical, biotechnology, and medical device industries, announced that it has entered into a definitive agreement to sell its U.S. medical device testing operations to NAMSA, a Toledo, Ohio-based MedTech testing, clinical, and regulatory consulting firm. Under the agreement, NAMSA will acquire WuXi AppTec’s medical device testing facilities in Minnesota and Georgia. Wilson Sonsini Goodrich & Rosati advised WuXi AppTec on the transaction.

The Wilson Sonsini team that advised WuXi AppTec on the transaction includes:

Corporate/M&A
Weiheng Chen
Jie Zhu
Chun Teng
Yang Liao

Antitrust
Beau Buffier

Data, Privacy, and Cybersecurity
Matt Staples
Nikolaos Theodorakis
Michael O’Brien
Diya Jajal

Employee Benefits and Compensation
Michael Klippert
Mark Cornillez-Ty
Jason Chan
Laura Yun

Employment and Trade Secret Litigation  
Matt Gorman
Quinn Christie

Environmental
Martin Sul

FDA/Regulatory
Eva Yin

Real Estate
James McCann
Moncarol Wang

Regulatory
Stephen Heifetz
Nimit Dhir
Jahna Hartwig

Tax
Myra Sutanto Shen
Beau Brawner

Technology Transactions – Biotech
John Wehrli
Taylor Arterburn
James Dunlop

Technology Transactions – IT
Barath Chari
Rodrigo Valle

For more information, please see WuXi AppTec’s news release. Additional coverage can be found on Fierce Biotech.